Biotechnology

Cargene Closes a US$19.2M Pre-A Round Led by BioTrack Capital

SINGAPORE and SHANGHAI and BOSTON, Dec. 14, 2021 /PRNewswire/ -- Cargene Biopharma Inc.  ("Cargene") announced today the close of an over-subscribedUS$19.2 million pre-Series A funding round. The financing was led by BioTrack Capital, with participation from Hyfinity Inv...

2021-12-14 09:00 3719

Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy

INCHEON, South Korea, Dec. 13, 2021 /PRNewswire/ -- Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN). The partnership is based on an...

2021-12-14 08:55 1482

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Dec. 13, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.   Located in Minsk, capital of the Republic of Belarus and a m...

2021-12-13 22:16 2069

"Finally" User-friendly, Methylcellulose-free Solutions for Meat Substitutes using Citri-Fi® Citrus Fiber

RIVER FALLS, Wis., Dec. 13, 2021 /PRNewswire/ -- Fiberstar, Inc., the leader of high performing citrus fibers, launches new methylcellulose-free solutions to create clean label meat substitutes. "This launch comes at a time when food manufacturers are scrambling for ways to improve meat substitut...

2021-12-13 22:04 2447

IASO Biotherapeutics and Innovent Biologics Announced Updated Clinical Data of BCMA CAR-T Therapy in Oral Presentation at 2021 ASH Annual Meeting

SAN JOSE and SAN FRANCISCO and NANJING, China, Dec. 12, 2021 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a clinical-stage biopharmaceutical company focused on discovering, developing, and manufacturing innovative medicines and Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-cla...

2021-12-13 12:14 2032

Physicians At St. David's Medical Center Among First In Nation To Implant Neurostimulator Technology For Advanced Heart Failure

AUSTIN, Texas, Dec. 13, 2021 /PRNewswire/ -- Doctors at St. David's Medical Center recently became among the first in the U.S. to implant a new neurostimulator technology to help treat advanced heart failure. The Barostim System is the only technology approved by the Food and Drug Administration ...

2021-12-13 10:08 1905

Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors

* ATG-017 is an oral small molecule ERK1/2 inhibitor; Opdivo® is aPD-1 checkpoint inhibitor * Combination study to begin in H12022 SHANGHAI and HONG KONG, Dec. 13, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, global biopharmaceutical co...

2021-12-13 08:30 2427

StemiRNA Therapeutics appoints Dr. Jack Hu as Chief Financial Officer

SHANGHAI and BOSTON, Dec. 12, 2021 /PRNewswire/ -- StemiRNA, a leader in research and development of mRNA therapeutics, welcomes Dr.Jack Hu as Chief Financial Officer. Dr. Hu brings nearly two decades of experience in healthcare investment research, financial management and corporate strategy. Dr...

2021-12-13 07:00 1629

Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2021-12-12 18:50 3410

Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

* TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objective response rate * Safety profile was favorable and ...

2021-12-12 09:00 5097

The New Era Biotechnology deepens cooperation between China and Belarus in the Great Stone China Belarus Industrial Park (CBIP)

MINSK, Belarus, Dec. 10, 2021 /PRNewswire/ -- As an enterprise in CBIP, the New Era Biotechnology Co., Ltd. participated in the fourth edition of the China International Import Expo (CIIE) which opened inShanghai on November 5, 2021.       Located in Minsk, capital of the Republic of Belarus a...

2021-12-10 23:38 4374

Qiming's Portfolio Company CANbridge Pharmaceuticals Lists on Main Board of HKEx

SHANGHAI, Dec. 10, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leadingChina-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong Stock Exchange. The issue price isHK$ 12.18 per share,...

2021-12-10 15:15 3984

Trajan to acquire LEAP PAL Parts

MELBOURNE, Australia, Dec. 9, 2021 /PRNewswire/ -- Global analytical science and device company Trajan Group Holdings Limited (ASX: TRJ) (Trajan or the Company) has entered into a binding agreement to acquire the business of LEAP PAL Parts and Consumables, LLC ("LPP"), based in Raleigh North Caro...

2021-12-09 21:00 1650

The innovative software "CAAS vFFR" by Pie Medical Imaging for the non-invasive physiological assessment of intermediate coronary lesions is the subject of FAST III, a multicenter European clinical trial which will investigate the effectiveness of the vessel Fractional Flow Reserve (vFFR) guided revascularization as compared to conventional FFR guided revascularization

MAASTRICHT, Netherlands, Dec. 9, 2021 /PRNewswire/ --  Pie Medical Imaging ("PMI"), a global leader in cardiac imaging, part of the Esaote Group, today announced the beginning of FASTIII, a multicenter randomized clinical trial which willinvestigate the use of angiography-based vessel fractional ...

2021-12-09 21:00 2397

Sciwind Biosciences Completes Enrollment in Phase 2 Clinical Trial of XW003 in Type 2 Diabetes Patients

HANGZHOU, China and SAN FRANCISCO, Dec. 9, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the completion of patient enrollment in its Phase 2 clin...

2021-12-09 20:00 2001

Frost & Sullivan Honors Disruptive Organizations in the Region with Prestigious Industry Awards

16 companies will be recognized at the final Frost & Sullivan Virtual Awards Ceremony of the year, which will be broadcasted live on YouTube at6:00 p.m. (GMT +8),16 December 2021. SINGAPORE, Dec. 9, 2021 /PRNewswire/ -- Frost & Sullivan Best Practices Awards will be honoring 16 leading organizat...

2021-12-09 19:32 1994

Lunit Named to the 2021 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

SEOUL, South Korea, Dec. 9, 2021 /PRNewswire/ -- CB Insights today named Lunit to its third annual Digital Health 150 , which showcases the 150 most promising private digital healt...

2021-12-09 11:24 1912

WuXi AppTec Receives 2021 Global Customer Value Leadership Award from Frost & Sullivan

SHANGHAI, Dec. 8, 2021 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry, announced that it is a recipient of the 2021 Global CRDMO Customer Value Leadership Award from Frost & Sullivan, a global ...

2021-12-09 08:00 1875

Treadwell Therapeutics Announces A Presentation at the 2021 SABCS Annual Meeting Featuring a Clinical Trial Update on CFI-402257, a Best-in-Class TTK inhibitor

NEW YORK and HONG KONG, Dec. 8, 2021 /PRNewswire/ -- Treadwell Therapeutics, today announced a presentation for the Company's CFI-402257 program, an oral, best-in-class TTK inhibitor, at the 2021 San Antonio Breast Cancer Symposium (SABCS) being held from December 7-10, 2021.  This presentation w...

2021-12-08 20:00 2118

China's Largest Commercial GMP Plasmid Manufacturing Facility is Put into Operation, GenScript ProBio Expanding Manufacturing Capacity Again

NANJING, China, Dec. 8, 2021 /PRNewswire/ -- On December 7th, the "Opening Ceremony of GenScript ProBio Plasmid Commercial GMP Manufacturing facility and Open Day" was rounded off. GenScript ProBio at the opening ceremony announced thatthe largest commercial GMP plasmid manufacturing facility in ...

2021-12-08 18:22 1502
1 ... 166167168169170171172 ... 281